Joana Carvalho, PhD, managing science editor —

The Foundation for Sarcoidosis Research is urging adults with sarcoidosis to participate in a new study that will investigate how lymphocytes — one of the main types of immune cells found in the body — control inflammation and if this level of control is part of the reason…

As part of a new agreement with AdVita Lifescience, Relief Therapeutics will acquire the intellectual rights for the specifications and potential applications of an inhaled formulation of RLF-100 (aviptadil). Relief has been collaborating with NeuroRx to advance the development of RLF-100 to treat patients with severe…

The Foundation for Sarcoidosis Research (FSR) is launching a series of mindfulness and meditation workshops — all as free, live webinars — to support people with sarcoidosis and those caring for them. The workshop series will focus on discussing the physical and mental benefits of meditation and…

Women with sarcoidosis are more likely to die in hospital from heart complications and also to experience sudden cardiac death than male patients, while men are more likely to have a heart defibrillator device, a study reports. These findings highlight the importance of recognizing how sex differences…

ATYR1923, aTyr Pharma’s lead investigational therapy for pulmonary sarcoidosis, is safe and well-tolerated, according to interim data from a Phase 1b/2a clinical trial. ATYR1923 is a first-in-class disease-modifying therapy  in development for the treatment of different types of interstitial lung diseases…

The soluble interleukin 2 receptor (sIL-2R) is more sensitive and specific than the angiotensin-converting enzyme (ACE), one of the most common diagnostic biomarkers of sarcoidosis, at identifying people who might have the disease, a study found. The findings were reported in the study, “Sensitivity and specificity of…

Depression and anxiety may worsen the quality of life and lung function of patients with pulmonary sarcoidosis, a study has found. The findings of the study, “Psychological burden associated with worse clinical outcomes in sarcoidosis,” were published in the journal BMJ Open Respiratory Research. Statistics…

The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Ofev (nintedanib) for the treatment of patients with sarcoidosis and other types of progressive fibrosing interstitial lung diseases (ILDs). The breakthrough designation is given to medications that provide significant advantages over…

People with hepatitis C who develop sarcoidosis may be safely treated with adalimumab, marketed by Abbvie as Humira, a case report suggests. The case was described in a study, “Sarcoidosis with concomitant hepatitis C infection treated successfully with adalimumab,” which was published in the Journal…

Patients with advanced sarcoidosis have limited daily life physical activity, mostly because their lungs’ maximal oxygen uptake is reduced, a study shows. The findings of the study, “Daily life physical activity in patients with chronic stage IV sarcoidosis: A multicenter cohort study,” were published in the journal Health…